Manufacture of the substance shall take place in accordance with the Good Manufacturing Practice and in accordance with the dossier submitted.

Failure to comply with these provisions will render this certificate void.

This certificate is renewed from **4 November 2015** according to the provisions of Resolution AP-CSP (07) 1, and of Directive 2001/83/EC and Directive 2001/82/EC and any subsequent amendment, and the related guidelines.

This certificate has two annexes, the first of 1 page and the second of 5 pages.
This certificate has:
lines.

On behalf of the
Director of EDQM

Strasbourg, 12 September 2019

DECLARATION OF ACCESS *(to be filled in by the certificate holder under their own responsibility)*

**IOL CHEMICALS AND PHARMACEUTICALS LTD**, as holder of the certificate of suitability

**R1-CEP 2008-316-Rev 03 for Ibuprofen**

hereby authorises UAB "Corpus Medica" 61-2 Sukilelių ave, LT- 49333, Kaunas, Lithuania
(*name of the pharmaceutical company*)

to use the above-mentioned certificate of suitability in support of their application(s) for the following Marketing Authorisation(s): (*name of product(s) and marketing number(s), if known*)

Tuingestin 400mg film-coated Tablets

The holder also certifies that no significant changes to the operations as described in the CEP dossier have been made since the granting of this version of the certificate.

Date and Signature (*of the CEP holder*):

For IOL Chemicals and Pharmaceuticals Ltd

Name- Kushal Kumar Rana 17.06.2020
(President Quality)

Authorised Signatory

Address: 7 Allée Kastner, CS 30026
F-67081 Strasbourg (France)
Tel: +33 (0) 3 88 41 30 30 – Fax: +33 (0) 3 88 41 27 71 - e-mail: cep@edqm.eu
Internet: http://www.edqm.eu